Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Standaert

Showing results (11-20 of 188) with videos related to

Pageof 19
Sort By:
Experimental Neurology|October 9, 2007
Design of clinical trials of gene therapy in Parkinson diseaseTravis B Lewis, David G Standaert
Disease Models & Mechanisms|April 30, 2010
Target validation: the Parkinson disease perspectiveDavid G Standaert, Talene A Yacoubian
Current Opinion in Neurology|May 23, 2024
Levodopa infusion therapies for Parkinson diseaseMarissa N Dean, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society|May 2, 2020
Ten Unsolved Questions About Neuroinflammation in Parkinson's DiseaseEtienne C Hirsch, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society|December 13, 2016
Cholinergic regulation of striatal dopamine release: New light in dark basementsChelsea N Zimmerman, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society|November 12, 2019
Bridging the gaps: More inclusive research needed to fully understand Parkinson's diseaseRebecca M Gilbert, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2013
Metabolomics and the search for biomarkers in Parkinson's diseaseAmy W Amara, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society|June 16, 2022
John Q. Trojanowski, MD, PhD (1946-2022)Howard I Hurtig, David G Standaert
Neurobiology of Disease|March 14, 2017
Dysregulation of BET proteins in levodopa-induced dyskinesiaDavid A Figge, David G Standaert
Annals of Neurology|October 26, 2016
Glucocerebrosidase, Parkinson disease, and the "senses and intellect"David G Standaert, David S Geldmacher
Pageof 19

Showing results (11-20 of 188) with videos related to

Sort By:
Pageof 19
Experimental Neurology|October 9, 2007
Design of clinical trials of gene therapy in Parkinson diseaseTravis B Lewis, David G Standaert
Disease Models & Mechanisms|April 30, 2010
Target validation: the Parkinson disease perspectiveDavid G Standaert, Talene A Yacoubian
Current Opinion in Neurology|May 23, 2024
Levodopa infusion therapies for Parkinson diseaseMarissa N Dean, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society|May 2, 2020
Ten Unsolved Questions About Neuroinflammation in Parkinson's DiseaseEtienne C Hirsch, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society|December 13, 2016
Cholinergic regulation of striatal dopamine release: New light in dark basementsChelsea N Zimmerman, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society|November 12, 2019
Bridging the gaps: More inclusive research needed to fully understand Parkinson's diseaseRebecca M Gilbert, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2013
Metabolomics and the search for biomarkers in Parkinson's diseaseAmy W Amara, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society|June 16, 2022
John Q. Trojanowski, MD, PhD (1946-2022)Howard I Hurtig, David G Standaert
Neurobiology of Disease|March 14, 2017
Dysregulation of BET proteins in levodopa-induced dyskinesiaDavid A Figge, David G Standaert
Annals of Neurology|October 26, 2016
Glucocerebrosidase, Parkinson disease, and the "senses and intellect"David G Standaert, David S Geldmacher
Pageof 19